EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study

Lemchukwu Amaeshi iD, Lauren Laufer iD, Kateryna Fedorov iD, Alex Sisto iD, David Levitz iD, Rosmi Mathew iD, Karen Wright, Dennis Cooper iD, Mendel Goldfinger iD, Ioannis Mantzaris iD, R Alejandro Sica iD, Kira Gritsman iD und 9 weitere

JMIR Cancer · 06.01.2026 · 12 · e68101-e68101

DOI: 10.2196/68101 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JMIR Cancer, online erschienen am 06.01.2026. Verfasst von Lemchukwu Amaeshi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Montefiore Medical Center, Bronx, NY, United States. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Health Services Accessibility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with cancer often face significant financial challenges, known as financial toxicity (FT), which is associated with reduced quality of life. Patients with hematologic malignancies (HMs) are especially vulnerable due to intensive and prolonged treatments, frequent hospital visits, and a high risk of complications. While FT affects many in the general population, it is particularly severe among racial and ethnic minorities, especially those below the poverty line. To our knowledge, no studies have specifically examined FT in this vulnerable group in the United States.

Objective

This study aimed to evaluate the severity of FT in patients receiving treatment for HMs in a socioeconomically underserved population, explore sociodemographic factors that may predict the severity of FT, and evaluate the subjective experiences of these patients as they relate to FT.

Methods

We conducted a prospective, observational, longitudinal study at the Montefiore Cancer Center’s outpatient department in the Bronx, New York, from October 1, 2022, to October 30, 2023. Participants included either adult patients newly diagnosed (ND) with HMs or those already diagnosed, undergoing cellular therapy (CT). The severity of FT was assessed using the validated Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire. Additionally, an investigator-designed questionnaire was developed to gather sociodemographic data and evaluate the subjective effects of financial burden on patient care. Patients in both the ND and CT groups were followed for 90 days. Data collection occurred at their initial presentation, as well as on days 30 and 90.

Results

Ninety patients participated in the study (ND=52 and CT=38). The median age was 59 (IQR 44-66) years, with 27% (n=24) African American and 55% (n=48) Hispanic. Overall, 75% (n=67) of participants experienced some degree of FT, most with mild FT at baseline (day 0, median COST-FACIT score=19.4). In the CT group, FT worsened significantly over time, with a decline in median COST-FACIT scores from 19.9 at day 0 to 15.5 on day 90 ( P =.02). In a multivariable linear regression model, race and ethnicity were a significant predictor of FT burden: identifying as African American or Hispanic was associated with a significantly lower COST-FACIT score (ie, higher FT) compared to non-Hispanic White participants (B=−3.08, P =.04, 95% CI −6.05 to −0.12). Additionally, over half of ND and CT participants reported difficulty affording basic necessities (ND: 28/52, 54%; CT: 23/38, 61%) and concerns regarding transportation access and costs (ND: 26/50, 52%; CT: n=18/38, 47%).

Conclusions

FT is prevalent among patients with HMs receiving care in underserved populations, and the burden is significantly higher among African American and Hispanic populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsHealth Services AccessibilityHumansMalePilot ProjectsFemaleMiddle AgedProspective StudiesAgedAdultQuality of LifeLongitudinal StudiesSocioeconomic Factors

Stichwörter der Autor:innen

African AmericanHispanicadherencecancercancer carecellular therapyfinancial literacyfinancial toxicityhematologic malignancieslongitudinal studymedical carequality of lifequestionnairesocioeconomicallysurvival

Autor:innen und Institutionen

  • Department of Medicine, Montefiore Medical Center, Bronx, NY, United States.
  • Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States.
  • Department of Medicine, University of California, Los Angeles, CA, United States.
  • Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY, 10467, United States, +1 (404) 778-1900.
  • Oncology, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States.

ORCID-Profile: Lemchukwu Amaeshi, Lauren Laufer, Kateryna Fedorov, Alex Sisto, David Levitz, Rosmi Mathew, Dennis Cooper, Mendel Goldfinger, Ioannis Mantzaris, R Alejandro Sica, Kira Gritsman, Marina Konopleva, Ridhi Gupta, Noah Kornblum, Chenxin Zhang, Mimi Kim, Amit Verma, Bruce Rapkin, Aditi Shastri, Nishi Shah

Zitieren

APA

Amaeshi, L., Laufer, L., Fedorov, K., Sisto, A., Levitz, D., Mathew, R., Wright, K., Cooper, D., Goldfinger, M., Mantzaris, I., Sica, R. A., Gritsman, K., Konopleva, M., Gupta, R., Kornblum, N., Zhang, C., Kim, M., Verma, A., Rapkin, B., …, & Shah, N. (2026). Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study. JMIR Cancer, 12, e68101-e68101. https://doi.org/10.2196/68101

Vancouver

Amaeshi L, Laufer L, Fedorov K, Sisto A, Levitz D, Mathew R, et al. Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study. JMIR Cancer. 2026;12:e68101-e68101. doi:10.2196/68101

BibTeX
@article{Amaeshi2026,
  author = {Amaeshi, Lemchukwu and Laufer, Lauren and Fedorov, Kateryna and Sisto, Alex and Levitz, David and Mathew, Rosmi and Wright, Karen and Cooper, Dennis and Goldfinger, Mendel and Mantzaris, Ioannis and Sica, R Alejandro and Gritsman, Kira and Konopleva, Marina and Gupta, Ridhi and Kornblum, Noah and Zhang, Chenxin and Kim, Mimi and Verma, Amit and Rapkin, Bruce and Shastri, Aditi and Shah, Nishi},
  title = {Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study},
  journal = {JMIR Cancer},
  year = {2026},
  volume = {12},
  pages = {e68101--e68101},
  doi = {10.2196/68101}
}
Kostenlos starten →